The National Institutes of Health (NIH) outlined its research goals for improving treatment for opioid use and abuse, as well as creating better, safer therapies for chronic pain.
The National Institutes of Health (NIH) Tuesday outlined its research goals for improving treatment for opioid use and abuse, as well as creating better, safer therapies for chronic pain.
The head of the NIH, Francis S. Collins, MD, PhD, and 2 other NIH leaders outlined in a JAMA column how $500 million in additional funding from Congress will be spent in its Helping to End Addiction Long-term (HEAL) Initiative. The initiative, a multifaceted research program encompassing pre-clinical, clinical, drug repurposing, and community-based approaches, launched in April 2018.
At a recent summit about drug abuse, “leaders from both the public and private sectors affirmed that research is essential to the effort to end this public health crisis. It will take 'all hands on deck' to make this happen, which is why HEAL seeks to foster innovative partnerships with other government agencies, academic institutions, industry, communities, and patient advocates,” the authors wrote.
The letter pointed out that more than 25 million US adults are affected by daily pain, and more than 2 million individuals have opioid use disorder (OUD). Only a fraction of those with OUD receive medication-assisted treatment (MAT).
Ending addiction will require preventive efforts in more areas than just healthcare, the NIH said, including education, mental health, stigma, childhood trauma, and socioeconomics.
It will also involve effective management of acute and chronic pain, including supporting the discovery and development of targets for non-addictive pain management. The NIH will collect data to determine what factors lead acute pain to transition to chronic pain and how to prevent it from happening.
Other parts of the plan include:
NIH said it will also expand a pilot study attempting to determine the best approach for neonatal opioid withdrawal syndrome (NOWS), also referred to as neonatal abstinence syndrome. The study is designed to assess the prevalence of NOWS, understand current approaches to managing NOWS, and develop protocols for larger-scale studies that will determine best practices for clinical care of affected infants.
Reference
Collins FS, Koroshetz WJ, Volkow ND. Helping to end addiction over the long-term: the research plan for the NIH HEAL Initiative [published online June 12, 2018]. JAMA. doi: 10.1001/jama.2018.8826.
The American Journal of Managed Care® is issuing a call for papers for a themed issue on Substance Use Disorders, with a tentative publication date of November 2018.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More